Literature DB >> 33322371

Prospects for NK Cell Therapy of Sarcoma.

Mieszko Lachota1, Marianna Vincenti2, Magdalena Winiarska3, Kjetil Boye4, Radosław Zagożdżon5, Karl-Johan Malmberg2,6.   

Abstract

Natural killer (NK) cells are innate lymphoid cells with potent antitumor activity. One of the most NK cell cytotoxicity-sensitive tumor types is sarcoma, an aggressive mesenchyme-derived neoplasm. While a combination of radical surgery and radio- and chemotherapy can successfully control local disease, patients with advanced sarcomas remain refractory to current treatment regimens, calling for novel therapeutic strategies. There is accumulating evidence for NK cell-mediated immunosurveillance of sarcoma cells during all stages of the disease, highlighting the potential of using NK cells as a therapeutic tool. However, sarcomas display multiple immunoevasion mechanisms that can suppress NK cell function leading to an uncontrolled tumor outgrowth. Here, we review the current evidence for NK cells' role in immune surveillance of sarcoma during disease initiation, promotion, progression, and metastasis, as well as the molecular mechanisms behind sarcoma-mediated NK cell suppression. Further, we apply this basic understanding of NK-sarcoma crosstalk in order to identify and summarize the most promising candidates for NK cell-based sarcoma immunotherapy.

Entities:  

Keywords:  Natural Killer (NK) cells; adoptive cell therapy; cancer; cell-mediated cytotoxicity; chimeric antigen receptor (CAR); immunotherapy; sarcoma; solid tumors; tumor microenvironment (TME)

Year:  2020        PMID: 33322371      PMCID: PMC7763692          DOI: 10.3390/cancers12123719

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  242 in total

1.  Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors.

Authors:  Antonio Pérez-Martínez; Inmaculada de Prada Vicente; Lucía Fernández; Marta González-Vicent; Jaime Valentín; Roberto Martín; Hannah Maxwell; Julián Sevilla; José Luis Vicario; Miguel Ángel Díaz
Journal:  Exp Hematol       Date:  2012-07-04       Impact factor: 3.084

2.  Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction.

Authors:  Stefan Welte; Sabrina Kuttruff; Inja Waldhauer; Alexander Steinle
Journal:  Nat Immunol       Date:  2006-10-22       Impact factor: 25.606

Review 3.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

4.  NK cell and macrophages confer prognosis and reflect immune status in osteosarcoma.

Authors:  Xianliang Yang; Wenbin Zhang; Panfeng Xu
Journal:  J Cell Biochem       Date:  2018-12-16       Impact factor: 4.429

5.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  MMP9 mediates MICA shedding in human osteosarcomas.

Authors:  Dahui Sun; Xu Wang; Haixia Zhang; Lijuan Deng; Yan Zhang
Journal:  Cell Biol Int       Date:  2011-06       Impact factor: 3.612

7.  Early activation and interferon-γ production of tumor-infiltrating mature CD27 high natural killer cells.

Authors:  Yoshihiro Hayakawa; Marimo Sato-Matsushita; Kazuyoshi Takeda; Yoichiro Iwakura; Hideaki Tahara; Tatsuro Irimura
Journal:  Cancer Sci       Date:  2011-08-21       Impact factor: 6.716

Review 8.  Partners in crime: TNFα-based networks promoting cancer progression.

Authors:  Adit Ben-Baruch
Journal:  Cancer Immunol Immunother       Date:  2019-12-09       Impact factor: 6.968

9.  Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway.

Authors:  John M Idso; Shunhua Lao; Nathan J Schloemer; Jeffrey Knipstein; Robert Burns; Monica S Thakar; Subramaniam Malarkannan
Journal:  Oncotarget       Date:  2020-05-19

10.  Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.

Authors:  Chihab Klose; Susanne Berchtold; Marina Schmidt; Julia Beil; Irina Smirnow; Sascha Venturelli; Markus Burkard; Rupert Handgretinger; Ulrich M Lauer
Journal:  BMC Cancer       Date:  2019-12-03       Impact factor: 4.430

View more
  4 in total

1.  Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.

Authors:  Xiuxia Lu; Mengmeng Liu; Jing Yang; Yi Que; Xing Zhang
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

Review 2.  Perspectives for 3D-Bioprinting in Modeling of Tumor Immune Evasion.

Authors:  Rafał Staros; Agata Michalak; Kinga Rusinek; Krzysztof Mucha; Zygmunt Pojda; Radosław Zagożdżon
Journal:  Cancers (Basel)       Date:  2022-06-26       Impact factor: 6.575

Review 3.  Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.

Authors:  Natacha Omer; Wayne Nicholls; Bronte Ruegg; Fernando Souza-Fonseca-Guimaraes; Gustavo Rodrigues Rossi
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

4.  Bioinformatic Analysis Reveals Central Role for Tumor-Infiltrating Immune Cells in Uveal Melanoma Progression.

Authors:  Mieszko Lachota; Anton Lennikov; Karl-Johan Malmberg; Radoslaw Zagozdzon
Journal:  J Immunol Res       Date:  2021-06-11       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.